

PB 26 of 2022

National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2022 (No. 3)

I, NIKOLAI TSYGANOV, Assistant Secretary (Acting), Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health and Aged Care, make the following determination.

Dated 29 March 2022

**NIKOLAI TSYGANOV**

Assistant Secretary (Acting)

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name…………………………………………………………………………….………………1

2 Commencement 1

3 Authority 1

4 Schedule 1

Schedule 1—Amendments 2

National Health (Continued Dispensing - Emergency Measures) Determination 2020 2

1 Name

1. This instrument is the *National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2022 (No. 3)*.
2. This instrument may also be cited as PB 26 of 2022.

2 Commencement

1. Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information | | |
| --- | --- | --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. *The whole of this instrument* | *1 April 2022* | *1 April 2022* |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

1. Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 89A(3) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Continued Dispensing – Emergency Measures) Determination 2020

1. Schedule 1, omit entry for Alendronic acid with colecalciferol and calcium
2. Schedule 1, entry for Amino acid formula with vitamins and minerals without phenylalanine and tyrosine

*omit:*

|  |  |  |
| --- | --- | --- |
|  | Sachets containing oral powder 34 g, 30 (TYR express 20) | Oral |

1. Schedule 1, entry for Amino acid formula with vitamins and minerals without valine, leucine and isoleucine

*omit:*

|  |  |  |
| --- | --- | --- |
|  | Sachets containing oral powder 34 g, 30 (MSUD express 20) | Oral |

1. Schedule 1, entry for Budesonide

*insert as the first entry:*

|  |  |  |
| --- | --- | --- |
|  | Capsule (modified release) 3 mg | Oral |

1. Schedule 1, entry for Cromoglycic acid

*omit:*

|  |  |  |
| --- | --- | --- |
|  | Pressurised inhalation containing sodium cromoglycate 5 mg per dose, 112 doses (CFC‑free formulation) | Inhalation by mouth |

1. Schedule 1, omit entry for Docosahexaenoic acid with carbohydrate
2. Schedule 1, omit entry for Etacrynic acid
3. Schedule 1, after entry for Fluticasone furoate with umeclidinium and vilanterol in the form Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses

*insert:*

|  |  |  |
| --- | --- | --- |
|  | Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth |

1. Schedule 1, after entry for Imatinib in the form Tablet 400 mg (as mesilate)

*insert:*

|  |  |  |
| --- | --- | --- |
|  | Tablet 600 mg (as mesilate) | Oral |

1. Schedule 1, after entry for Mupirocin in the form Nasal ointment 20 mg (as calcium) per g, 5 g

*insert:*

|  |  |  |
| --- | --- | --- |
| Mycobacterium bovis (Bacillus Calmette and Guerin (BCG)) Danish 1331 strain | Single dose pack containing powder for irrigation 30 mg, 4 vials | Intravesical |

1. Schedule 1, entry for Pancreatic extract

*omit:*

|  |  |  |
| --- | --- | --- |
|  | Capsule (containing enteric coated minimicrospheres) providing not less than 40,000 BP units of lipase activity | Oral |

1. Schedule 1, after entry for Pancrelipase in the form Capsule (containing enteric coated microtablets) providing not less than 25,000 BP units of lipase activity

*insert:*

|  |  |  |
| --- | --- | --- |
|  | Capsule (containing enteric coated microtablets) providing not less than 25,000 BP units of lipase activity (s19A) | Oral |